Intratumoral poly-N-acetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine model

Journal of Immunotherapy

Volumn 28, Issue 4, 2005, Pages 359-367

  Van Bruggen, Ivonne ^a   Nelson, Delia J ^a,b,c   Currie, Andrew J ^a   Jackaman, Connie ^a   Robinson, Bruce W S ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

IL 2; Slow release gel; Tumor immunology

Indexed keywords

CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; N ACETYLGLUCOSAMINE; POLYMER; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; FEMALE; GEL; GENE TARGETING; IMMUNOCOMPETENT CELL; INFLAMMATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALIGNANT MESOTHELIOMA; MICROENVIRONMENT; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; SLOW DRUG RELEASE; T LYMPHOCYTE; TUMOR GROWTH;

EID: 21844463060     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000170361.37832.ec     Document Type: Article

References (35)

1. Marzo AL, Lake RA, Robinson BW, et al. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 1999;59:1071-1079.
2. Marzo AL, Lake RA, Lo D, et al. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol. 1999;162:5838-5845.
3. Wick M, Dubey P, Koeppen H, et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med. 1997;186:229-238.
4. Nguyen LT, Elford AR, Murakami K, et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med. 2002;195:423-435.
5. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003;21:807-839.
6. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev. 2002;188:97-113.
7. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol. 2000;165:6047-6055.
8. Jackaman C, Bundell CS, Kinnear BF, et al. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol. 2003;171:5051-5063.
9. Caminschi I, Venetsanakos E, Leong CC, et al. Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am J Respir Cell Mol Biol. 1998;19:738-746.
10. Furumoto K, Soares L, Engleman EG, et al. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest. 2004;113:774-783.
11. Ganss R, Ryschich E, Klar E, et al. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002;62:1462-1470.
12. Maitre N, Brown JM, Demcheva M, et al. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Clin Cancer Res. 1999;5:1173-1182.
13. Robinson BW, Mukherjee SA, Davidson A, et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother. 1998;21:211-217.
14. Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg. 1988;208:121-135.
15. Semino C, Martini L, Queirolo P, et al. Adoptive immunotherapy of advanced solid tumors: an eight-year clinical experience. Anticancer Res. 1999;19:5645-5649.
16. Wysocki PJ, Karczewska-Dzionk A, Mackiewicz-Wysocka M, et al. Human cancer gene therapy with cytokine gene-modified cells. Expert Opin Biol Ther. 2004;4:1595-1607.
17. Caminschi I, Venetsanakos E, Leong CC, et al. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12. Am J Respir Cell Mol Biol. 1999;21:347-356.
18. Leong CC, Marley JV, Loh S, et al. The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer. Immunol Cell Biol. 1997;75:356-359.
19. Ettinghausen SE, Rosenberg SA. Immunotherapy and gene therapy of cancer. Adv Surg. 1995;28:223-254.
20. Nowak AK, Lake RA, Kindler HL, et al. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 2002;29:82-96.
21. Kosty MP, Herndon JE2nd, Vogelzang NJ, et al. High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study: Cancer and Leukemia Group B 9631. Lung Cancer. 2001;34:289-295.
22. Bretti S, Berruti A, Dogliotti L, et al. Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. Tumori. 1998;84:558-561.
23. Thatcher N, Taylor P, Carroll KB, et al. Interleukin-2 in malignant pleural mesothelioma (and adenocarcinoma of the lung). The use of intrapleural and continuous intravenous infusions: preliminary results. Cancer Treat Rev. 1989;16(Suppl A):161-162.
24. Mulatero CW, Penson RT, Papamichael D, et al. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer. 2001;31:67-72.
25. Davidson JA, Musk AW, Wood BR, et al. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother. 1998;21:389-398.
26. Mukherjee S, Nelson D, Loh S, et al. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther. 2001;8:580-588.
27. Cole DJ, Gattoni-Celli S, McClay EF, et al. Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Clin Cancer Res. 1997;3:867-873.
28. Salem ML, Kadima AN, Zhou Y, et al. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol. 2004;172:5159-5167.
29. Nguyen CL, Bui JT, Demcheva M, et al. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. J Immunother. 2001;24:420-429.
30. Lukacs KV, Porter CD, Pardo OE, et al. In vivo transfer of bacterial marker genes results in differing levels of gene expression and tumor progression in immunocompetent and immunodeficient mice. Hum Gene Ther. 1999;10:2373-2379.
31. Lawton JA, Ghosh P. Novel therapeutic strategies based on Toll-like receptor signaling. Curr Opin Chem Biol. 2003;7:446-451.
32. Ikeda H, Chamoto K, Tsuji T, et al. The critical role of type 1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004;95:697-703.
33. Rosenberg SA. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2. Semin Oncol. 1986;13:200-206.
34. Rosenberg SA. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am. 2000;6(Suppl 1):S2-S7.
35. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA. 2004;101(Suppl 2):14639-14645.